MGMT and central nervous system cancer: The results showed that for glioma patients in the TCGA cohort, all of the ARGs were prognostic-risk factors, except for TNFRSF21. Thereafter, we evaluated differences in risk score between different clinicopathological characteristics of glioma patients in the training and validation cohorts, including IDH mutation status, 1p/19q codeletion, MGMT promoter methylation, age, WHO grade, and histology.